FDA
-
-
-
-
-
-
-
Jefferies on Mineralys Therapeutics, Inc. (MLYS): 'Historical Trends Suggests M&A Is Still Statistically Possible Before PDUFA'
-
-
-
-
-
-
-
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer
-
-
-
-
-
-
-
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
-
-
-
-
-
-
-
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
-
-
-
-
-
-
-
Jefferies Reiterates Hold Rating on Mineralys Therapeutics, Inc. (MLYS)
-
-
-
-
-
-
-
Mineralys Therapeutics (MLYS) Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
-
-
-
-
-
-
-
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College
-
328,334 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

